The in vivo results were consistent with the observations in vitro: tumours treated with the miR-590 agomir were more sensitive to erlotinib treatment than the miR-NC agomir-treated tumours (704.70 ± 32.99 mm3 vs. 348.70 ± 53.72 mm3, P < 0.05, Fig. 4h) because EHD1 expression was low. This evidence concerns the gene EHD1 and neoplasm.